Freshfields LLP has advised argenx. Wilson Sonsini Goodrich & Rosati, P.C. has advised Forte Biosciences. Argen NV ADR (NASDAQ: ARGX) and Forte Biosciences, Inc. (NASDAQ: FBRX)...
argenx Acquires Forte Biosciences for $2.2 Billion, Adding First-in-Class Anti-CD122 Antibody to Immunology Pipeline
Whitehawk Therapeutics Announces $87.5 Million Private Placement Financing
Wilson Sonsini Goodrich & Rosati has advised Whitehawk Therapeutics. Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company, has announced that it has entered into a securities...
Windward Bio Group Secures USD 165 Million in Series B Financing Round
Homburger has advised Windward Bio Group AG. Wilson Sonsini Goodrich & Rosati and BGParnter have advised OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds....
Gilead Sciences Acquires Arcellx in $7.8 Billion Deal
Wilson Sonsini Goodrich & Rosati has advised Arcellx on the transaction, and Ropes & Gray LLP has advised Gilead Sciences. Gilead Sciences (Nasdaq: GILD) has entered...
Forte Biosciences Announces $150 Million Public Offering of Common Stock
Wilson Sonsini Goodrich & Rosati has advised Forte Biosciences. Paul Hastings LLP has advised Guggenheim Securities and Barclays. Forte Biosciences, Inc., a clinical-stage biopharmaceutical company specializing...
Veradermics Launches Oversubscribed $150 Million Series C Financing Round
Wilson Sonsini Goodrich & Rosati advised lead investor SR One on the transaction. Veradermics, a dermatologist-founded, late clinical-stage biopharmaceutical company developing therapeutics for common dermatologic conditions,...
Expedition Therapeutics Closes $165 Million Series A Financing for COPD Therapy
Wilson Sonsini Goodrich & Rosati has advised Sofinnova Investments, Novo Holdings, and Forbion. Expedition Therapeutics, a biotechnology company specializing in therapies for novel inflammatory and respiratory...
Crystalys Therapeutics Launches With $205 Million Series A Financing to Advance Gout Treatment
Latham & Watkins has advised Crystalys Therapeutics. Wilson Sonsini Goodrich & Rosati has advised Novo Holdings and SR One. Crystalys Therapeutics Inc., a clinical-stage biopharmaceutical company,...
Avenzo Therapeutics Raises $60 Million in Series B Financing
Wilson Sonsini Goodrich & Rosati has advised SR One. Avenzo Therapeutics, Inc., a clinical-stage biotechnology company focused on developing next-generation oncology therapies, has closed a $60...
Odyssey Therapeutics Closes $213 Million Series D Financing
Wilson Sonsini Goodrich & Rosati has advised SR One as lead investor. Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the closing of a $213...
LENZ Therapeutics Secures FDA Approval for VIZZ in Presbyopia Treatment
Wilson Sonsini Goodrich & Rosati has advised LENZ Therapeutics on the transaction. LENZ Therapeutics announced that the U.S. Food and Drug Administration has approved VIZZ (aceclidine...
Avalyn Pharma Closes $100 Million Oversubscribed Series D Financing
Goodwin Procter advised Avalyn Pharma Inc., and Wilson Sonsini Goodrich & Rosati has advised SR One and Novo Holdings on the transaction. Avalyn Pharma Inc., a...